Hanmi Surprises Again, Signing Big Diabetes Deal With Sanofi
This article was originally published in PharmAsia News
South Korea's Hanmi Pharmaceutical is making the history books. Following its record-setting agreements with Lilly and Boehringer Ingelheim earlier this year, it has now inked a substantially bigger licensing out pact worth up to €3.9bn with Sanofi for its diabetes Quantum Project. While the deal will buoy the portfolio of the leading global diabetes player, it offers no quick fix, analysts caution.
You may also be interested in...
At year's end the French pharma also announced a restructuring of its broad diabetes collaboration with South Korea’s Hanmi. In a deal involving two other French companies, OSE out-licensed global development and commercial rights to an IL-7 antagonist to Servier.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
SK Biopharmaceuticals vice-president Haein Shin talks to Scrip about the company’s long journey to developing and launching novel innovative CNS drugs in global markets and what is behind its achievement, which is seen as unprecedented in the South Korean pharma industry.